Krystal Biotech, Inc. (the “Company” or “Krystal”) is a clinical-stage biotechnology company leading the field of redosable gene delivery for the treatment of serious rare diseases. The Company uses its patented platform that is based on engineered HSV-1, to create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell’s own machinery then transcribes and translates the encoded effector to treat or prevent disease. The lead product candidate, beremagene geperpavec (previously KB103), now known as VYJUVEK, is a topical gene therapy to treat dystrophic epidermolysis bullosa, a rare and severe monogenic skin disease for which there may not be a treatment to affect the outcome of the disease.